Semaglutide vs Tirzepatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ozempic, Wegovy
A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Also: Mounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Key Comparison Insights
- Both Semaglutide and Tirzepatide are FDA approved medications.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Both are GLP-1 class medications compared in weight management studies.
Detailed Comparison
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1. | Tirzepatide activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation. The dual mechanism enhances glucose-dependent insulin release while reducing glucagon and slowing gastric emptying. |
| Common Dosing | 1-2.4 mg weekly (after titration) Once weekly | 5-15 mg weekly (after titration) Once weekly |
| Administration | Subcutaneous injection weekly, or oral (Rybelsus) | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term / chronic use |
| Best Time to Take | Morning, same day each week | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | STEP trials: 15-17% weight loss. FLOW trial: 24% reduction in kidney disease progression (Jan 2025 approval). Wegovy pill: 16.6% weight loss (Dec 2025 approval). Oral Rybelsus approved for CV risk reduction (Oct 2025). | SURMOUNT trials showed average weight loss of 20-26% body weight. SURMOUNT-OSA showed 25-29 fewer sleep apnea events per hour. SURPASS-2 showed superior A1C reduction compared to semaglutide. SUMMIT trial (2024-25) showed 38% reduction in CV death or worsening heart failure in HFpEF patients with obesity - data added to EU labeling Jan 2026. |
Frequently Asked Questions: Semaglutide vs Tirzepatide
What is the difference between Semaglutide and Tirzepatide?
Semaglutide is a weight loss peptide that a glp-1 receptor agonist with multiple fda approvals including weight loss, t2d, cv risk reduction, and kidney protection. wegovy pill approved dec 2025 as first oral glp-1 for weight loss. Tirzepatide is a weight loss peptide that a dual gip/glp-1 receptor agonist representing the next generation of incretin-based therapies. shows superior weight loss compared to semaglutide in head-to-head trials. first medication approved for obstructive sleep apnea. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide or Tirzepatide?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide is typically used for weight loss purposes, while Tirzepatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide and Tirzepatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide and Tirzepatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.